Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 14/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10345168 | 0.79 | PDE10A (0.82) | PDE10ASMN1; SMN2MAPTRAB9APOLB | |
| SCHEMBL10309545 | 0.73 | PDE10A (1.00) | PDE10ASMN1; SMN2CYP2C9NOS1NOS2 | |
| SCHEMBL10309548 | 0.73 | PDE10A (0.70) | PDE10A | |
| SCHEMBL15038167 | 0.72 | PDE10A (0.59) | PDE10ASMN1; SMN2CYP2C9NOS1NOS2 | |
| SCHEMBL15038168 | 0.71 | PDE10A (0.54) | PDE10ASMN1; SMN2MAPTRAB9ACYP2C9 | |
| SCHEMBL7458054 | 0.71 | PDE10A (0.62) | PDE10ALMNA | |
| SCHEMBL7514548 | 0.70 | PDE10A (0.61) | PDE10ASMN1; SMN2CYP2C9NOS1NOS2 | |
| SCHEMBL10309394 | 0.69 | PDE10A (1.00) | PDE10A | |
| SCHEMBL18634604 | 0.67 | PDE10A (0.57) | PDE10ASMN1; SMN2POLBCYP2C9NOS1 | |
| SCHEMBL12066505 | 0.66 | LMNA (0.56) | PDE10ASMN1; SMN2MAPTRAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570156-B2 | Substituted imidazo[1,2-a]pyridines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2020-02-25 | — | — | US | disclosed |
| EP-3210984-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20180072759-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2018-03-15 | — | — | US | disclosed |
| EP-3210984-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-2663565-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20160102106-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2016-04-14 | — | — | US | disclosed |
| US-9249162-B2 | Substituted [1,2,4]triazolo[1,5-a]pyridines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140288062-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2014-09-25 | — | — | US | disclosed |
| US-8765760-B2 | [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| WO-2012096929-A2 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072759-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | PDE10A 2086/4885SMN1; SMN2 568/4885MAPT 778/4885 |
| US-10570156-B2 | Substituted imidazo[1,2-a]pyridines as PDE-10 inhibitors | PDE3A, PDE2A, PDE5A | PDE10A 5/4885SMN1; SMN2 368/4885MAPT 2800/4885 |
| US-20140288062-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | PDE10A 2086/4885SMN1; SMN2 568/4885MAPT 778/4885 |
| US-20160102106-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | PDE10A 2086/4885SMN1; SMN2 568/4885MAPT 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.